Beautiful Virgin Islands

Tuesday, Jun 24, 2025

Rare Blood Clot Risk Higher From Coronavirus Than Vaccine, Says UK Study

Rare Blood Clot Risk Higher From Coronavirus Than Vaccine, Says UK Study

The risk of rare blood clotting following the COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza, according to a new University of Oxford study published on Thursday.
The risk of rare blood clotting following the COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza, according to a new University of Oxford study published on Thursday.

The research found that the rare blood clotting known as Cerebral Venous Thrombosis (CVT) is more common after COVID-19 than in any of the comparison groups, with 30 per cent of these cases occurring in the under 30s.

Compared to the current COVID-19 vaccines being administered, this risk is between 8-10 times higher, and compared to the baseline, approximately 100 times higher.

The study follows reports of possible links between the Oxford/AstraZeneca vaccine and rare cases of CVT, which are undergoing deeper investigations by the medicines regulators even as the jabs have been ruled as safe and effective.

"There are concerns about possible associations between vaccines and CVT, causing governments and regulators to restrict the use of certain vaccines. Yet, one key question remained unknown: 'What is the risk of CVT following a diagnosis of COVID-19?''," said Paul Harrison, one of study authors as Professor of Psychiatry and Head of the Translational Neurobiology Group at the University of Oxford.

"We've reached two important conclusions. Firstly, COVID-19 markedly increases the risk of CVT, adding to the list of blood clotting problems this infection causes.

"Secondly, the COVID-19 risk is higher than we see with the current vaccines, even for those under 30; something that should be taken into account when considering the balances between risks and benefits for vaccination," he said.

The study authors, led by Professor Harrison and Dr Maxime Taquet from Oxford University's Department of Psychiatry and the NIHR Oxford Health Biomedical Research Centre, counted the number of CVT cases diagnosed in the two weeks following diagnosis of COVID-19, or after the first dose of a vaccine. They then compared these to calculated incidences of CVT following influenza, and the background level in the general population.

"The signals that COVID-19 is linked to CVT, as well as portal vein thrombosis - a clotting disorder of the liver - is clear, and one we should take note of," said Dr Maxime Taquet, also from the Translational Neurobiology Group.

In the study of over 500,000 COVID-19 patients, CVT occurred in 39 in a million patients. In over 480,000 people receiving a COVID-19 mRNA vaccine, such as Pfizer/BioNTech or Moderna, CVT occurred in four in a million, and CVT has been reported to occur in about five in a million people after first dose of the Oxford/AstraZeneca COVID-19 vaccine.

"Compared to the mRNA vaccines, the risk of a CVT from COVID-19 is about 10 times greater. Compared to the AZ-Oxford (Oxford/AstraZeneca) vaccine, the risk of a CVT from COVID-19 is about eight times greater," the findings note.

However, the researchers said that all comparisons must be interpreted cautiously since data is still accruing. An important factor that requires further research is whether COVID-19 and vaccines lead to CVT by the same or different mechanisms. There may also be under-reporting or mis-coding of CVT in medical records, and therefore uncertainty as to the precision of the results, the study authors note.

The findings come as numerous countries have limited use of the Oxford/AstraZeneca vaccine to certain age groups or paused its rollout. Denmark has dropped the jab from its vaccination programme permanently following reports of very rare cases of blood clots.

Earlier this month, the UK''s Medicines and Healthcare products Regulatory Agency (MHRA) said the vaccine is still safe and effective but said that people under-30 will be offered an alternative, where possible, as an additional precaution.

The overall advice, including from the World Health Organisation (WHO), remains in favour of continued vaccinations as the experts concluded that the life-saving benefits of the Oxford/AstraZeneca vaccine continue to outweigh the risks.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
BBC Demands Perplexity AI Immediately Stop Using Its Content
Telegram Founder: I Will Leave My Fortune to Over 100 of My Children
Political Turmoil Resurfaces in Belgium Amid Economic Concerns
Fed policymakers divided on timing of interest rate cuts
Trump signals imminent agreement with Harvard University
Inheritance tax referendum alarms Swiss billionaire community
Japan cancels bilateral security meeting amid US defence demands
AI skeptic Emily Bender warns that ‘the emperor has no clothes’
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
Plans to Sell Dutch Embassy in Bangkok Face Local Opposition
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump's $5 Million 'Trump Card' Visa Program Draws Nearly 70,000 Applicants
DGCA Finds No Major Safety Concerns in Air India's Boeing 787 Fleet
Airlines Reroute Flights Amid Expanding Middle East Conflict Zones
Elon Musk's xAI Seeks $9.3 Billion in Funding Amid AI Expansion
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Taiwan Imposes Export Ban on Chips to Huawei and SMIC
Israel has just announced plans to strike Tehran again, and in response, Trump has urged people to evacuate
Netanyahu Signals Potential Regime Change in Iran
Juncker Criticizes EU Inaction on Trump Tariffs
EU Proposes Ban on New Russian Gas Contracts
×